News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
11,984 Results
Type
Article (2147)
Company Profile (4)
Press Release (9833)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (4392)
Career Advice (20)
Deals (620)
Drug Delivery (1)
Drug Development (1965)
Employer Resources (9)
FDA (375)
Job Trends (410)
News (7366)
Policy (826)
Tag
Academia (26)
Allergies (1)
Alliances (1227)
ALS (1)
Alzheimer's disease (3)
Approvals (378)
Artificial intelligence (6)
Autoimmune disease (4)
Bankruptcy (1)
Best Places to Work (130)
Biotechnology (2)
Cancer (10)
Cardiovascular disease (1)
Career advice (20)
CAR-T (1)
Cell therapy (1)
Clinical research (1602)
Collaboration (5)
COVID-19 (165)
C-suite (15)
Data (12)
Denatured (3)
Diagnostics (64)
Diversity, equity & inclusion (3)
Earnings (845)
Employer branding (4)
Employer resources (9)
Events (672)
Executive appointments (23)
FDA (382)
Funding (4)
Gene therapy (1)
GLP-1 (20)
Government (117)
Guidances (1)
Healthcare (190)
HIV (2)
Immuno-oncology (1)
Infectious disease (171)
Influenza (1)
Intellectual property (1)
Interviews (2)
IPO (107)
Job creations (282)
Job search strategy (20)
JPM (1)
Layoffs (28)
Legal (270)
Management (3)
Manufacturing (2)
Medical device (42)
Medtech (42)
Mergers & acquisitions (513)
Metabolic disorders (2)
Multiple sclerosis (1)
Neurodegenerative disease (1)
Neuropsychiatric disorders (1)
Neuroscience (6)
NextGen: Class of 2026 (143)
Non-profit (15)
Obesity (2)
Opinion (28)
Ovarian cancer (2)
Patents (1)
Patient recruitment (2)
Peanut (1)
People (1973)
Pharmaceutical (2)
Phase 1 (469)
Phase 2 (637)
Phase 3 (675)
Pipeline (11)
Postmarket research (142)
Preclinical (123)
Prostate cancer (1)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (1)
Real estate (147)
Recruiting (3)
Regulatory (499)
Research institute (45)
Resumes & cover letters (2)
RSV (5)
Series A (1)
Series B (2)
Startups (165)
Tariffs (1)
Vaccines (48)
Venture capital (1)
Date
Last 7 days (1)
Last 30 days (5)
Last 365 days (92)
2026 (5)
2025 (104)
2024 (142)
2023 (173)
2022 (1101)
2021 (976)
2020 (753)
2019 (472)
2018 (391)
2017 (490)
2016 (523)
2015 (925)
2014 (657)
2013 (594)
2012 (583)
2011 (662)
2010 (663)
Location
Africa (62)
Asia (683)
Australia (189)
California (28)
Canada (24)
China (6)
Delaware (1)
Europe (3562)
Florida (3)
Georgia (1)
Illinois (4)
Indiana (1)
Maryland (3)
Massachusetts (29)
Minnesota (2)
Missouri (1)
New Jersey (11)
New York (4)
North Carolina (4)
Northern California (17)
Pennsylvania (10)
South America (44)
Southern California (7)
Texas (1)
United States (110)
Washington State (10)
11,984 Results for "glaxosmithkline".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
Surface Oncology today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors.
March 31, 2022
·
4 min read
FDA
GlaxoSmithKline: A Look at its Consumer Health Demerger and a Shingles Approval
It’s a busy week for GlaxoSmithKline, although much of it is related to the upcoming demerger of its Consumer Healthcare business. Here’s a look.
July 26, 2021
·
3 min read
·
Mark Terry
Business
PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development
PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline (GSK), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.
April 5, 2022
·
2 min read
Biotech Bay
Codexis Earns Milestone Payment from GlaxoSmithKline
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK).
July 7, 2021
·
2 min read
Job Trends
MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology’s Monoclonal Antibody Treatment for Patients with COVID‑19
Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection.
December 7, 2021
·
1 min read
FDA
FDA Adcomm Returns Mixed Vote on GSK’s CKD Drug - Updated
An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.
October 26, 2022
·
3 min read
·
Mark Terry
Drug Development
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
June 22, 2020
·
8 min read
GSK’s RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk
GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy, GSK’s respiratory syncytial virus (RSV) vaccine (recombinant, AS01E adjuvanted), to include adults aged 50-59 at increased risk for RSV disease.
February 26, 2024
·
5 min read
Business
GSK Swoops in to Save Spero, Late-Stage Antibiotic
Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr.
September 22, 2022
·
2 min read
·
Alex Keown
Policy
ViiV Healthcare Announces Health Canada Approval for APRETUDE (Cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi as shareholders, announced that Health Canada has granted approval for APRETUDE for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.
May 13, 2024
·
10 min read
1 of 1,199
Next